Literature DB >> 30896751

Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer.

Alexander T Pearson1, Randy F Sweis1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30896751     DOI: 10.1001/jamaoncol.2019.0130

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  5 in total

1.  Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug.

Authors:  D Perlstein; O Shlagman; Y Kogan; K Halevi-Tobias; A Yakobson; I Lazarev; Z Agur
Journal:  PLoS One       Date:  2019-12-26       Impact factor: 3.240

2.  Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy.

Authors:  Whitney Barham; Ruifeng Guo; Sean S Park; Joerg Herrmann; Haidong Dong; Yiyi Yan
Journal:  Front Immunol       Date:  2021-02-02       Impact factor: 7.561

3.  Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors.

Authors:  Saro Kasparian; Cesar Gentille; Ethan Burns; Eric H Bernicker
Journal:  JTO Clin Res Rep       Date:  2020-02-22

Review 4.  Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?

Authors:  Mo-Xuan Wang; Shu-Yue Gao; Fan Yang; Run-Jia Fan; Qin-Na Yang; Tian-Lan Zhang; Nian-Song Qian; Guang-Hai Dai
Journal:  World J Clin Oncol       Date:  2022-09-24

Review 5.  Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors.

Authors:  Pan Shen; Liang Han; Xin Ba; Kai Qin; Shenghao Tu
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.